Furthermore, comparative microarray-based studies in canine and human diffuse large B-cell lymphomas (DLBCL) revealed the activation of the NF-KB pathway24,25 as well as the dysregulation of pathways potentially bearing therapeutic and prognostic value, such as the PI3K/AKT, Notch and JAK/STAT pathways24, in both species. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.